The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)

PURPOSE OF REVIEW: In this review, we analyzed the current landscape of non-PD-(L)1 targeting immunotherapy. RECENT FINDINGS: The advent of immunotherapy has completely changed the standard approach toward advanced NSCLC. Inhibitors of the PD-1/PD-L1 axis have quickly taken place as first-line treat...

Descripción completa

Detalles Bibliográficos
Autores principales: De Giglio, Andrea, Di Federico, Alessandro, Nuvola, Giacomo, Deiana, Chiara, Gelsomino, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Lung Cancer (H Borghaei, Section Editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397682/
https://www.ncbi.nlm.nih.gov/pubmed/34453261
http://dx.doi.org/10.1007/s11912-021-01124-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397682/
https://www.ncbi.nlm.nih.gov/pubmed/34453261
http://dx.doi.org/10.1007/s11912-021-01124-9

Ejemplares similares